Navigation Links
Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
Date:12/15/2008

BRIDGEWATER, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S., an affiliate of sanofi-aventis, one of the world's leading pharmaceutical companies, announced today that starting January 1, 2009, it has increased access to its non-oncology Patient Assistance Programs (PAP)s to include eligible uninsured patients with incomes up to 250% of the Federal Poverty Level.

These PAPs assist patients with limited financial resources in gaining access to needed sanofi-aventis U.S. prescription medicines by focusing on individual patients and acting as a resource for those patients and their advocates. Uninsured individuals with income levels of up to $26,000 and uninsured families of four with combined income of up to $53,000 may be eligible to receive sanofi-aventis U.S. prescription drugs at no charge through the expanded U.S. Traditional PAP.*

"Sanofi-aventis U.S. remains committed to making our prescription medicines available to uninsured and low income patients through our PAPs," stated Greg Irace, President and CEO of sanofi-aventis U.S. "We have taken several steps to help patients with the greatest financial need access these medications."

The sanofi-aventis U.S. Patient Assistance Programs include medicines for many different disease states, including: Diabetes, Rheumatoid Arthritis, Urology, Dermatology, Blood Clotting (Deep Vein Thrombosis, Pulmonary Embolism), and Allergies. For more information, please contact the sanofi-aventis U.S. Traditional PAP at 1-800-221-4025.

PACT+(R) (Providing Access to Cancer Therapy), is Sanofi-aventis U.S.'s PAP for Cancer medications. PACT+ provides access to our oncology brands for eligible low income patients with an income of no greater than 500 percent of the Federal Poverty Level. PACT+ also provides reimbursement support services plus offers help in identifying a variety of alternative services and resources to support the specific needs of cancer patients. For more information on PACT+, please call 1-800-996-6626.

In addition, sanofi-aventis U.S. is a proud participant in The Partnership for Prescription Assistance which brings together America's pharmaceutical companies, doctors, other health care providers, patient advocacy organizations and community groups to help qualifying patients who lack prescription coverage get the medicines they need through the public or private program that's right for them. Call 1-888-477-2669 or visit www.pparx.org.

*Federal Poverty Limits change annually and are issued by the US Department of Health and Human Services.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com

Contact: Marc Greene, sanofi-aventis, 212-551-4780


'/>"/>
SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
2. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
3. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
4. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
5. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
6. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
7. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
8. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
9. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
10. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
11. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: